The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Rusfertide, a novel hepcidin mimetic peptide, has been shown to decrease serum iron levels in healthy individuals, which suggests it may help decrease erythropoiesis in patients with polycythemia vera (PV).1 The three-part phase II REVIVE trial (NCT04057040), previously reported by the MPN Hub, is an ongoing study evaluating the safety and efficacy of rusfertide in patients with phlebotomy-dependent PV.
Recently, Kremyanskaya et al.1 published updated results from Parts 1 and 2 in the New England Journal of Medicine, which are summarized below.
Table 1. REVIVE trial Part 2 endpoints*
HCT, hematocrit. |
|||
Part 2 endpoint (% unless otherwise stated) |
Rusfertide (n = 30) |
Placebo (n = 29) |
p value |
---|---|---|---|
Response rate |
60 |
17 |
0.002 |
Patients requiring no phlebotomy |
93 |
48 |
- |
Mean absolute change in HCT from baseline (absolute percentage point) |
0.3±3.1 |
2.0±2.6 |
- |
Median time to loss of response (weeks) |
Not reached |
4.4 |
- |
Median time until phlebotomy requirement and first HCT above 45% (weeks) |
8.1 |
8.1 |
- |
Key learnings |
---|
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content